Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.56 |
| ▸ | MDM4 | O15151 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18148920 | 1.00 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29423590 | 1.00 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL119709 | 1.00 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL119708 | 1.00 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29528567 | 0.97 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL260631 | 0.97 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL178733 | 0.97 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL178698 | 0.97 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29401258 | 0.97 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29359997 | 0.97 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583900-B2 | Peptide conjugates and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250367259-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2025-12-04 | — | — | US | disclosed |
| US-20250325683-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | SCRIPPS RESEARCH INST (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320252-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | SCRIPPS RESEARCH INST (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4622673-A1 | NOVEL CARRIERS FOR NUCLEIC ACID AND/OR PROTEIN DELIVERY | Ludwig-Maximilians-Universität München (DE) | 2025-10-01 | — | — | EP | disclosed |
| US-12337028-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-06-24 | — | — | US | disclosed |
| US-12329823-B2 | Long-acting dual GIP/GLP-1 peptide conjugates and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2024110492-A9 | NOVEL CARRIERS FOR NUCLEIC ACID AND/OR PROTEIN DELIVERY | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2025-01-23 | — | — | WO | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| US-20230057847-A1 | GLP2 RECEPTOR AGONISTS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2023-02-23 | — | — | US | disclosed |
| WO-2022257979-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4069726-A2 | GLP2 RECEPTOR AGONISTS AND METHODS OF USE | The Scripps Research Institute (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-4069275-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2022-10-12 | — | — | EP | disclosed |
| EP-4069274-A1 | PEPTIDE CONJUGATES AND METHODS OF USE | The Scripps Research Institute (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-115052615-A | Peptide conjugates and methods of use | 斯克利普斯研究所 | 2022-09-13 | — | — | CN | disclosed |
| CN-115052886-A | GLP2 receptor agonists and methods of use | 斯克利普斯研究所 | 2022-09-13 | — | — | CN | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-114929259-A | Novel multifunctional oligopeptides | 艾缇亚(上海)制药有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12337028-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | SGMS1, SGMS2, PHOSPHO1 | KMT2A 3238/4885MDM2 2400/4885MDM4 1392/4885 |
| US-20230057847-A1 | GLP2 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GRPR | KMT2A 3248/4885MDM2 3189/4885MDM4 4823/4885 |
| US-12583900-B2 | Peptide conjugates and methods of use | GIPR, GLP1R, GCG | KMT2A 1061/4885MDM2 4495/4885MDM4 4869/4885 |
| US-20250325683-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | GLP1R, GIPR, GCGR | KMT2A 2554/4885MDM2 4061/4885MDM4 4750/4885 |
| US-20250367259-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | KMT2A 3006/4885MDM2 2282/4885MDM4 1419/4885 |
| US-12329823-B2 | Long-acting dual GIP/GLP-1 peptide conjugates and methods of use | GLP1R, GIPR, GCGR | KMT2A 2554/4885MDM2 4061/4885MDM4 4750/4885 |
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | KMT2A 3238/4885MDM2 2400/4885MDM4 1392/4885 |
| US-20250320252-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | GLP1R, GIPR, GCGR | KMT2A 2554/4885MDM2 4061/4885MDM4 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.